PRRUF:OTCMKTS
Immutep Ltd
$0.031
0.00%
(0.00) 1D
Sep 28, 2:19:26 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PRRUF...
Mkt. cap
26.51M
Avg. vol.
83.00
Volume
20.00
52-wk high
$0.33
52-wk low
$0.03
Beta
2.36
Shares outstanding
1.47B
No. of employees
19
Mkt. cap
26.51M
Avg. vol.
83.00
Volume
20.00
52-wk high
$0.33
52-wk low
$0.03
Beta
2.36
Shares outstanding
1.47B
No. of employees
19
News stories
From web sources and news partners
https://www.dars.gov.et/
·
2 months ago
IMMP Q2 2026 Earnings: Clinical-Stage Loss Slightly Misses Estimates - Surprise Factor Analysis
Profile
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
About Immutep Ltd